CombiMatrix Preliminary Q3 Revenues Rise 15 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix today said that preliminary revenues for the third quarter was up 15 percent year over year, driven by increased microarray testing volumes.

The Irvine, Calif.-based firm said that for the three months ended Sept. 30, total revenues are expected to be $1.5 million, compared to $1.3 million a year ago, as microarray testing volumes rose to 1,145 billable tests from 857 billable tests a year ago, a 34 percent increase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.